Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAURA: AZD9291 vs Standard of Care in First-Line EGFR-Mutated Advanced NSCLC
NCT02296125Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing AZD9291+ placebo with Standard of Care + placebo AZD9291 (2 arms). Primary endpoints: Median Progression Free Survival and Percentage of Participants in Progression Free Survival at 18 months. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02296125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296125.